| Identification | More | [Name]
Fluticasone | [CAS]
90566-53-3 | [Synonyms]
(6s,9s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
FLUTICASONE
FluticasonePropionate98.5%
Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6.alpha.,11.beta.,16.alpha.,17.alpha.)-
(6S,9S,10S,11S,13S,14S,16R,17R)-6,9-Difluoro-17-(fluoromethylsulfanylcarbonyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
6α,9-Difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioic acid S-(fluoromethyl) ester
6α,9-Difluoro-16α-methyl-11β-hydroxy-17-hydroxy-3-oxoandrosta-1,4-diene-17β-carbothioic acid S-(fluoromethyl) ester | [Molecular Formula]
C25H31F3O5S | [MDL Number]
MFCD01862254 | [Molecular Weight]
500.57 | [MOL File]
90566-53-3.mol |
| Chemical Properties | Back Directory | [Melting point ]
237-239 °C | [Boiling point ]
553.2±50.0 °C(Predicted) | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Acetonitrile (Slightly), Chloroform (Slightly) | [form ]
Solid | [pka]
11.66±0.70(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic, Unstable in Solution | [InChIKey]
WMWTYOKRWGGJOA-KENGUEFRNA-N | [SMILES]
C[C@]12C[C@H](O)[C@]3([C@](C[C@@H](C4[C@]3(C)C=CC(=O)C=4)F)([H])[C@]1([H])C[C@@H](C)[C@@]2(C(=O)SCF)OC(=O)CC)F |&1:1,3,5,6,8,10,19,22,24,r| | [CAS DataBase Reference]
90566-53-3(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Uses]
therapeutic for asthma and allergic rhinitis Flonase | [Definition]
ChEBI: A trifluorinated corticosteroid used in the form of its propionate ester for treatment of allergic rhinitis. | [Brand name]
Cutivate (Altana); Flonase (GlaxoSmithKline); Flovent (GlaxoSmithKline). | [in vivo]
Fluticasone (1 mg/kg; intranasal dropping; 7 d) suppresses rhinovirus-induced airways inflammation in vivo but also impairs anti-viral immune responses and increases viral titres, leading to mucus hypersecretion[4].
| Animal Model: | C57BL/6 mice[4] | | Dosage: | 1 mg/kg | | Administration: | Intranasal dropping; 1 h before infection with rhinovirus 1B; 7 days | | Result: | Suppressed BAL neutrophil numbers and inhibited rhinovirus-induced airway inflammation. |
|
|
|